

# **Dalmia Bharat**

**BSE SENSEX S&P CNX** 57,654 16,986

CMP: INR1,870 TP: INR2,155 (+15%)

**BUY** 



#### Stock Info

Bloomberg	DALBHARA IN
Equity Shares (m)	187
M.Cap.(INRb)/(USDb)	350.6 / 4.3
52-Week Range (INR)	1989 / 1213
1, 6, 12 Rel. Per (%)	4/23/38
12M Avg Val (INR M)	465
Free float (%)	44.1

### Financials Snapshot (INR b)


rilialiciais Silapsilot (livit b)					
Y/E MARCH	FY23E	FY24E	FY25E		
Sales	133.4	145.3	163.1		
EBITDA	23.1	28.9	35.0		
Adj. PAT	6.8	8.9	12.0		
EBITDA Margin (%)	17.4	19.9	21.4		
Adj. EPS (INR)	36.1	47.6	64.1		
EPS Gr. (%)	-8.7	31.7	34.7		
BV/Sh. (INR)	883.4	918.0	969.1		
Ratios					
Net D:E	-0.0	-0.0	-0.0		
RoE (%)	4.2	5.3	6.8		
RoCE (%)	4.8	5.4	6.5		
Payout (%)	27.7	27.3	20.3		
Valuations					
P/E (x)	51.7	39.3	29.2		
P/BV (x)	2.1	2.0	1.9		
EV/EBITDA(x)	14.2	11.7	9.4		
EV/ton (USD)	100	85	82		
Div. Yield (%)	0.5	0.7	0.7		
FCF Yield (%)	-1.7	-1.5	1.2		

# Shareholding pattern (%)

As On	Dec-22	Sep-22	Dec-21
Promoter	55.9	55.9	56.0
DII	8.3	8.3	6.6
FII	12.4	12.3	13.5
Others	23.4	23.5	24.0

FII Includes depository receipts

## Stock performance (one-year)



# Divestment of non-core asset continues

- DALBHARA has entered into a binding agreement to sell its entire 42.36% stake in Dalmia Bharat Refractories (DBRL), an associate company, to Sarvapriya Healthcare Solutions, a promoter group company, for a total consideration of INR8b. This deal will be consummated within 30 days.
- The consideration will be received as: 1) INR1.6b on deal completion, and 2) INR6.4b converted into NCDs carrying a coupon of 8.5% p.a. payable quarterly. NCDs are redeemable in two tranches of INR3.2b each the first redeemable on or before 31<sup>st</sup> Dec'23 and the second on or before 30<sup>th</sup> Sep'24.
- In Jan'23, DBRL sold its Indian refractories business to RHI Magnesita India (RHI) through a share swap. RHI valued DBRL's Indian business at 24x FY22 EV/EBITDA. Accordingly, DALBHARA's stake in DBRL was valued at INR8.9b.

# Aims to become a pure play cement company with pan-India presence

- DALBHARA is committed to increasing its capacity to 75mtpa/110-130mtpa by FY27/FY31. The acquisition of JP group's 5.2mtpa cement capacity is nearing completion and the balance 4.2mtpa is under process.
- Its capital allocation policy focuses on 1) becoming a pan-India pure play cement company; 2) increasing presence in every market where it operates; and 3) maintaining a strong balance sheet with net debt/EBITDA of less than 2x. Discipline in capital allocation and execution remain in focus.
- In 1HFY22, DALBHARA sold a 5.2% stake (0.7%/4.5% in 2Q/1QFY22) in IEX for a total consideration of INR6.14b (IEX holding at 14.81% now). In Dec'21, it divested its stake in Hippo Stores via a slump sale to Hippostores Technology, a promoter group entity, for INR1.55b. NCDs worth INR1.2b (part of the consideration of Hippo stores sale) will be redeemable in Dec'23.

## Highlights from the management commentary

- It incorporated a pure play refractory company, DBRL, in FY22 (combined refractories business of Dalmia Bharat and OCL). DBRL divested its India refractory business in Jan'23 to RHI at an EV/EBITDA of 24x. DBRL received a lump-sum consideration of INR3.93b and 27m shares (14.36% stake) of RHI (valued at INR17.08b), locked for a period of six months.
- There will not be any delay in the deal completion. The carrying value of the investment as of Dec'22 stood at INR4b. Hence, there will be a long-term capital gain of INR4b and an estimated tax outflow of INR500m. The profit will be accrued in FY23, but the actual tax outgo will be in FY24 (post deal closing).
- Raw material and fuel security will be key focus areas. Recently, DALBHARA has been awarded a coal block in Madhya Pradesh.

## Valuations attractive; reiterate Buy

- We estimate the company's net cash (including investment in IEX) to be at INR4.1b in FY24 v/s estimated net debt of INR2.4b earlier. This will lead to EPS of INR47.6 in FY24E v/s INR47.1 earlier.
- We value DALBHARA at 12.5x Sep'24E EV/EBITDA to arrive at a TP of INR2,155 (from INR2,120 earlier). Reiterate our Buy rating on the stock.


Sanjeev Kumar Singh - Research analyst (Sanjeev.Singh@MotilalOswal.com)


Mudit Agarwal - Research analyst (Mudit.Agarwal@MotilalOswal.com)

# **Story in charts**

Exhibit 1: We expect ~11% volume CAGR over FY23-25

Exhibit 2: We estimate EBITDA CAGR of ~23% over FY23-25






Source: MOFSL, Company

Exhibit 3: Snapshot of DALBHARA's ongoing expansions - a mix of greenfield, brownfield, and debottlenecking

# **Cement Capacity Expansion Plan – 49\* MnT by FY24**





Region	Plant	Capacity	Commissioning	
Closing Capacity	FY22	35.9		
♀ East	Bokaro, JH	0.6		
North East	Adhunik, ML 0.2 H1FY2			
♀ East	Rajgangpur, OR	0.3		
Closing Capacity	H1FY23	37.0		
♀ East	Kapilas, OR	0.4		
♀ East	Medinipur, WB	0.6	FY23	
South	Belgaum, KA	0.9	1123	
North East	Calcom, AS	1.2		
Closing Capacity	FY23	40.0		
♀ East	Bokaro Line 2, JH	2.5		
South	Sattur, TN	2.0		
South	Ariyalur, TN	1.0	FY24	
<b>♀</b> South	Kadapa, AP	1.0		
♀ East	Vaishali, BR	2.5		
<b>Closing Capacity</b>	y FY24	49		


<sup>\*</sup> Does not include the cement capacity of 5.2Mnt of Jaiprakash Associates Limited for which definitive agreement has been signed. 47

Source: Company

Exhibit 4: Expect higher capex over FY23-25

Source: MOFSL, Company

Exhibit 5: Net debt and Net debt-to-EBITDA trend



Source: MOFSL, Company; E: MOFSL estimates, Note: estimates does not include JPA asset acquisition under-progress;

# **Financials and Valuations (Consolidated)**

Income Statement								(INR m)
Y/E March	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E
Net Sales	85,800	94,840	96,740	1,01,100	1,12,300	1,33,406	1,45,272	1,63,122
Change (%)	15.2	10.5	2.0	4.5	11.1	18.8	8.9	12.3
EBITDA	20,360	19,420	21,060	27,620	23,540	23,148	28,923	34,958
Margin (%)	23.7	20.5	21.8	27.3	21.0	17.4	19.9	21.4
Depreciation	12,130	12,960	15,280	12,500	12,360	13,079	15,013	16,751
EBIT	8,230	6,460	5,780	15,120	11,180	10,069	13,910	18,207
Int. and Finance Charges	7,080	5,510	4,380	2,950	1,970	2,250	3,055	3,374
Other Income - Rec.	2,740	2,440	2,170	1,810	1,550	1,400	1,740	1,940
PBT bef. EO Exp.	3,890	3,390	3,570	13,980	10,760	9,220	12,596	16,774
EO Expense/(Income)	0	0	0	-3,330	-3,940	-3,480	0	0
PBT after EO Exp.	3,890	3,390	3,570	17,310	14,700	12,700	12,596	16,774
Current Tax	1,080	1,120	1,140	2,120	1,870	2,127	3,275	4,361
Deferred Tax	-100	-1,220	50	3,330	1,230	0	0	0
Tax Rate (%)	27.8	33.0	31.9	12.2	12.7	16.7	26.0	26.0
Reported PAT	2,910	3,490	2,380	11,860	11,600	10,573	9,321	12,412
Minority and Associates	10	-410	-140	-130	-240	-50	-400	-400
PAT Adj. for EO items	2,920	3,080	2,240	8,400	7,420	6,773	8,921	12,012
Change (%)	563.6	5.5	-27.3	275.0	-11.7	-8.7	31.7	34.7
Margin (%)	3.4	3.2	2.3	8.3	6.6	5.1	6.1	7.4

Balance Sheet								(INR m)
Y/E March	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E	FY25E
Equity Share Capital	385	390	390	374	375	375	375	375
Total Reserves	1,02,965	1,06,000	1,05,650	1,27,726	1,56,495	1,65,144	1,71,629	1,81,206
Net Worth	1,03,350	1,06,390	1,06,040	1,28,100	1,56,870	1,65,519	1,72,004	1,81,580
Deferred capital investment subsidy	1,200	1,290	1,400	1,240	1,250	1,250	1,250	1,250
Deferred Liabilities	13,250	11,880	12,770	16,590	16,350	16,350	16,350	16,350
Minority Interest	-300	110	250	340	720	1,020	1,420	1,820
Total Loans	72,660	58,780	59,500	37,080	31,190	40,190	49,690	54,690
Capital Employed	1,90,160	1,78,450	1,79,960	1,83,350	2,06,380	2,24,329	2,40,714	2,55,690
Gross Block	1,62,870	1,66,210	1,66,440	1,86,160	1,99,100	2,24,237	2,66,125	2,84,196
Less: Accum. Deprn.	22,500	30,470	40,890	49,910	59,030	70,776	84,676	1,00,498
Net Fixed Assets	1,40,370	1,35,740	1,25,550	1,36,250	1,40,070	1,53,461	1,81,448	1,83,698
Capital WIP	1,730	5,200	17,400	10,060	10,470	15,000	7,000	18,000
Current Investment	34,080	23,150	26,980	32,930	43,990	42,990	40,490	40,490
Non-current Investment	970	1,090	1,610	7,410	13,060	16,540	9,290	9,290
Curr. Assets, Loans and Adv.	35,510	39,300	37,670	32,210	37,130	41,289	51,435	59,177
Inventory	7,790	10,320	9,740	7,600	9,450	10,965	10,746	12,067
Account Receivables	5,640	5,490	6,640	5,110	6,730	7,675	7,960	8,938
Cash and Bank Balance	3,540	4,690	4,030	2,470	1,600	3,127	13,330	18,706
Loans and Advances	18,540	18,800	17,260	17,030	19,350	19,521	19,398	19,466
Curr. Liability and Prov.	22,500	26,030	29,250	35,510	38,340	44,951	48,949	54,964
Account Payables	20,970	23,430	27,210	32,820	35,680	41,791	45,508	51,100
Provisions	1,530	2,600	2,040	2,690	2,660	3,160	3,441	3,864
Net Current Assets	13,010	13,270	8,420	-3,300	-1,210	-3,662	2,485	4,213
Appl. of Funds	1,90,160	1,78,450	1,79,960	1,83,350	2,06,380	2,24,329	2,40,714	2,55,690

E: MOFSL estimates

# **Financials and Valuations (Consolidated)**

Y/E March         FY18         FY19         FY20         FY21         FY22         FY23E         FY24E           Basic (INR)*         EPS         15.2         15.8         11.5         44.9         39.6         36.1         47.6           Cash EPS         78.1         82.3         89.8         111.7         105.6         105.9         127.7           BV/Share         536.2         545.6         543.8         684.6         837.2         883.4         918.0           DPS         1.7         2.0         2.0         1.3         9.0         10.0         13.0           Payout (%)         11.2         12.5         17.2         3.0         22.7         27.7         27.3           Valuation (x)*           P/E         118.4         162.8         41.7         47.2         51.7         39.3	64.1 153.5 969.1 13.0 20.3 29.2 12.2 1.9 2.0
EPS         15.2         15.8         11.5         44.9         39.6         36.1         47.6           Cash EPS         78.1         82.3         89.8         111.7         105.6         105.9         127.7           BV/Share         536.2         545.6         543.8         684.6         837.2         883.4         918.0           DPS         1.7         2.0         2.0         1.3         9.0         10.0         13.0           Payout (%)         11.2         12.5         17.2         3.0         22.7         27.7         27.3           Valuation (x)*           P/E         118.4         162.8         41.7         47.2         51.7         39.3	153.5 969.1 13.0 20.3 29.2 12.2 1.9
Cash EPS     78.1     82.3     89.8     111.7     105.6     105.9     127.7       BV/Share     536.2     545.6     543.8     684.6     837.2     883.4     918.0       DPS     1.7     2.0     2.0     1.3     9.0     10.0     13.0       Payout (%)     11.2     12.5     17.2     3.0     22.7     27.7     27.3       Valuation (x)*       P/E     118.4     162.8     41.7     47.2     51.7     39.3	153.5 969.1 13.0 20.3 29.2 12.2 1.9
BV/Share     536.2     545.6     543.8     684.6     837.2     883.4     918.0       DPS     1.7     2.0     2.0     1.3     9.0     10.0     13.0       Payout (%)     11.2     12.5     17.2     3.0     22.7     27.7     27.3       Valuation (x)*       P/E     118.4     162.8     41.7     47.2     51.7     39.3	969.1 13.0 20.3 29.2 12.2 1.9
DPS     1.7     2.0     2.0     1.3     9.0     10.0     13.0       Payout (%)     11.2     12.5     17.2     3.0     22.7     27.7     27.3       Valuation (x)*       P/E     118.4     162.8     41.7     47.2     51.7     39.3	13.0 20.3 29.2 12.2 1.9
Payout (%) 11.2 12.5 17.2 3.0 22.7 27.7 27.3  Valuation (x)*  P/E 118.4 162.8 41.7 47.2 51.7 39.3	20.3 29.2 12.2 1.9
Valuation (x)*       P/E     118.4     162.8     41.7     47.2     51.7     39.3	29.2 12.2 1.9
P/E 118.4 162.8 41.7 47.2 51.7 39.3	12.2 1.9
	12.2 1.9
- 1 - /-	1.9
Cash P/E 22.7 20.8 16.7 17.7 14.6	
P/BV 3.4 3.4 2.7 2.2 2.1 2.0	2.0
EV/Sales 4.0 3.7 3.4 2.9 2.5 2.3	2.0
EV/EBITDA 19.4 17.2 12.4 13.8 14.2 11.7	9.4
EV/t (USD) 172 166 135 110 100 85	82
Dividend Yield (%) 0.1 0.1 0.5 0.5 0.7	0.7
Return Ratios (%)	
RoIC 3.8 2.9 2.8 9.8 6.8 5.3 6.0	7.5
RoE 2.9 2.9 2.1 7.2 5.2 4.2 5.3	6.8
RoCE 4.5 3.5 3.3 9.0 6.3 4.8 5.4	6.5
Working Capital Ratios	
Asset Turnover (x) 0.5 0.5 0.6 0.5 0.6 0.6	0.6
Inventory (Days) 33 40 37 27 31 30 27	27
Debtor (Days) 24 21 25 18 22 21 20	20
Leverage Ratio (x)	
Current Ratio 1.6 1.5 1.3 0.9 1.0 0.9 1.1	1.1
Debt/Equity ratio 0.7 0.6 0.6 0.3 0.2 0.2 0.3	0.3
	(INR m)
Y/E March FY18 FY19 FY20 FY21 FY22 FY23E FY24E	FY25E
OP/(Loss) before Tax         3,890         3,390         3,570         13,640         11,460         9,220         12,596	16,774
Depreciation 12,130 12,960 15,280 12,500 12,370 13,079 15,013	16,751
Interest and Finance Charges 7,080 5,510 3,640 3,190 1,930 2,250 3,055	3,374
Direct Taxes Paid -860 -240 -660 440 240 -2,127 -3,275	-4,361
(Inc.)/Dec. in WC -3,590 1,500 2,740 7,810 -5,150 3,811 3,960	3,506
CF from Operations         18,650         23,120         24,570         37,580         20,850         26,232         31,348	36,042
Others -2,590 -2,220 -1,190 -1,540 -1,480 -1,150 -1,740	-1,940
CF from Operations incl. EO         16,060         20,900         23,380         36,040         19,370         25,082         29,608	34,102
	-30,000
Free Cash Flow 12,130 7,610 9,930 25,770 1,810 -5,918 -5,392	4,102
(Pur.)/Sale of Investments 3,950 10,320 -4,970 6,050 6,330 981 9,739	-16
Others 1,350 2,870 300 370 410 1,400 1,740	1,940
	-28,076
Issue of Shares 40 40 0 -4,000 50 0 0	0
Inc./(Dec.) in Debt -7,730 -13,870 120 -25,340 -5,800 9,188 9,606	5,159
Interest Paid -7,620 -5,420 -4,680 -3,960 -2,320 -2,250 -3,055	-3,374
Dividend Paid -330 -400 -930 0 -1,000 -1,874 -2,436	-2,436
Others 0 0 -430 -450 -350 0 0	0
CF from Fin. Activity -15,640 -19,650 -5,920 -33,750 -9,420 5,065 4,115	-650
Inc./Dec. in Cash 1,790 1,150 -660 -1,560 -870 1,528 10,203	5,376
Opening Balance         1,750         3,540         4,690         4,030         2,470         1,600         3,127	13,330
Closing Balance 3,540 4,690 4,030 2,470 1,600 3,127 13,330	18,706

Explanation of Investment Rating					
Investment Rating	Expected return (over 12-month)				
BUY	>=15%				
SELL	< - 10%				
NEUTRAL	< - 10 % to 15%				
UNDER REVIEW	Rating may undergo a change				
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation				

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at

http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at <a href="https://www.nseindia.com">www.nseindia.com</a>, <a href="https://www.nseindia.com">www.nseindia.com</a>, <a href="https://www.nseindia.com">www.nseindia.com</a>. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated. from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered brokerdealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

# Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

  MOFSL has not received compensation for investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- MOFSL has not engaged in market making activity for the subject company

27 March 2023 5

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

### **Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

### **Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022-3980 4263; <a href="https://www.motilaloswal.com">www.motilaloswal.com</a>. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai-400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeral Agarwal. Email Id: na@motilaloswal.com. Contact No: 022-40548085.

71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com. Contact No.:022-40548085.

Registration details of group entities:: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL: IN-DP-16-2015; NSDL: IN-DP-NSDL-152-2000; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products. Customer having any query/feedback/ clarification may write to <a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to <a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to <a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to <a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>.